COMPASS THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.46 USD | +0.69% |
|
-2.01% | -6.41% |
| Apr. 25 | Compass Therapeutics Gets FDA Fast-Track Designation for Biliary Tract Cancer Treatment | MT |
| Apr. 25 | Compass Therapeutics Gets FDA Fast-Track for Cancer Treatment | DJ |
Chart calendar Compass Therapeutics, Inc.
67ee92bbdda2239556098d13e9fe.ux7oQsa5y7_OJKnTYI7vS8pX5mwtMZBHIJgcLeUK_9I.3lGaKfTYj4j2RsyUB92pAYEOpRVDBPgBFslteINppZPJbYst9eyk6qNn4A~1932ecf29f9b5d7870658d4b5901ba45
Upcoming events on Compass Therapeutics, Inc.
Past events on Compass Therapeutics, Inc.
| 2024-04-16 | Cholangiocarcinoma Foundation Conference - Katie Kelley |
| 2024-04-16 | Cholangiocarcinoma Foundation Conference - Minori Rosales |
| 2024-04-16 11:00 am | Stifel Virtual Targeted Oncology Days Conference |
| 2024-03-21 09:00 am | Q4 2023 Earnings Release |
| 2024-03-13 10:40 am | Leerink Partners Global Biopharma Conference |
| 2023-11-16 07:00 am | Jefferies London Healthcare Conference |
| 2023-11-14 09:45 am | Stifel Healthcare Conference |
| 2023-11-09 07:30 am | Q3 2023 Earnings Release |
| 2023-09-27 02:25 pm | Cantor Global Healthcare Conference |
| 2023-09-11 04:00 pm | H.C. Wainwright Global Investment Conference |
| 2023-09-05 | Citi BioPharma Conference |
| 2023-08-07 | Wedbush PacGrow Healthcare Conference |
| 2023-08-03 08:00 am | Q2 2023 Earnings Release |
| 2023-06-15 10:00 am | Annual General Meeting |
| 2023-06-13 08:30 am | Bank of America and Mass General World Medical Innovation Forum |
| 2023-06-08 02:00 pm | Jefferies Global Healthcare Conference |
| 2023-05-09 | EF Hutton Global Conference |
| 2023-05-04 08:30 am | Q1 2023 Earnings Release |
| 2023-05-02 10:00 am | H.C. Wainwright BioConnect Investor Conference |
| 2023-04-26 11:00 am | Stifel Targeted Oncology Days |
Annual results
| Fiscal Period | December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 |
|
EBITDA Million USD | Released Forecast Spread | 0,00 | -81,3 -75,0 -8.42% | -40,9 -37,6 -8.7% | -49,7 -47,3 -5.11% | -67,6 |
|
EBIT Million USD | Released Forecast Spread | 0,00 | -81,9 -75,5 -8.43% | -41,7 -42,5 1.9% | -50,4 -48,6 -3.66% | -68,3 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -29,5 | -82,2 -75,7 -8.5% | -39,2 -41,2 4.7% | -42,5 -42,9 0.88% | -64,9 |
|
Net income Million USD | Released Forecast Spread | -29,5 | -82,2 -75,8 -8.48% | -39,2 -41,2 4.84% | -42,5 -42,4 -0.23% | -66,3 |
|
EPS USD | Released Forecast Spread | 0,00 | -1,31 -1,22 -7.27% | -0,37 -0,39 4.72% | -0,33 -0,33 0.86% | -0,48 |
| Announcement Date | 05/03/21 | 18/03/22 | 15/03/23 | 21/03/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
|
EBITDA Million USD | Released Forecast Spread | -12,9 -6,00 -114.62% | -7,02 -16,0 56.14% | -8,77 -8,00 -9.59% | -12,4 -10,2 -22.01% | -12,7 -11,8 -7.26% | -9,52 -13,8 31.14% | -13,2 -10,7 -22.96% | -11,8 -14,2 17.34% | -15,2 -12,8 -19.44% | -15,7 | -16,2 | -17,6 | -18,0 | -17,0 |
|
EBIT Million USD | Released Forecast Spread | -13,0 -6,62 -96.46% | -7,18 -13,2 45.71% | -8,99 -7,87 -14.22% | -12,6 -10,0 -25.75% | -12,9 -13,7 5.81% | -9,71 -13,7 29.17% | -13,3 -11,7 -14.15% | -11,9 -14,6 18.1% | -15,4 -13,9 -10.86% | -15,5 | -16,5 | -17,3 | -18,2 | -17,2 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -13,0 -6,64 -95.7% | -7,16 -13,0 45.03% | -8,49 -7,65 -11.02% | -12,0 -9,87 -21.32% | -11,6 -13,5 14.27% | -7,84 -13,2 40.55% | -11,3 -10,3 -9.67% | -9,96 -13,9 28.16% | -13,4 -12,2 -9.96% | -14,5 | -15,5 | -16,7 | -17,6 | -17,2 |
|
Net income Million USD | Released Forecast Spread | -13,0 -6,62 -96.02% | -7,16 -12,2 41.17% | -8,49 -8,76 3.03% | -12,0 -11,0 -9.11% | -11,6 -13,6 14.66% | -7,84 -13,2 40.79% | -11,3 -10,0 -12.3% | -9,96 -13,9 28.18% | -13,4 -12,0 -11.95% | -14,8 | -16,0 | -17,1 | -18,0 | -17,2 |
|
EPS USD | Released Forecast Spread | -0,05 -0,07 32.2% | -0,07 -0,13 46.15% | -0,08 -0,09 5.88% | -0,12 -0,11 -12.5% | -0,10 -0,11 10.45% | -0,06 -0,11 44.74% | -0,09 -0,08 -10.52% | -0,08 -0,11 25.33% | -0,11 -0,09 -17.86% | -0,11 | -0,12 | -0,12 | -0,12 | -0,11 |
| Announcement Date | 18/03/22 | 09/05/22 | 01/08/22 | 09/11/22 | 15/03/23 | 04/05/23 | 03/08/23 | 09/11/23 | 21/03/24 | - | - | - | - | - |
| Today 04:05 pm | EXELIXIS, INC.: Q1 2024 Earnings Release |
| 2024-04-30 | SUMMIT THERAPEUTICS INC.: Q1 2024 Earnings Release |
| 2024-04-30 | MACROGENICS, INC.: Q1 2024 Earnings Release (Projected) |
| 2024-04-30 | REGENXBIO INC.: Q1 2024 Earnings Release (Projected) |
| 2024-04-30 | DECIPHERA PHARMACEUTICALS, INC.: Q1 2024 Earnings Release (Projected) |
| 2024-05-01 07:00 am | NEUROCRINE BIOSCIENCES, INC.: Q1 2024 Earnings Release |
| 2024-05-01 04:05 pm | SAREPTA THERAPEUTICS, INC.: Q1 2024 Earnings Release |
| 2024-05-01 | ZENTALIS PHARMACEUTICALS, INC.: Q1 2024 Earnings Release (Projected) |
| 2024-05-01 | DENALI THERAPEUTICS INC.: Q1 2024 Earnings Release (Projected) |
| 2024-05-01 | GERON CORPORATION: Q1 2024 Earnings Release |
Past sector events for Compass Therapeutics, Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- CMPX Stock
- Calendar Compass Therapeutics, Inc.
